Extended Data Fig. 6: Tc9 ACT increases the infiltration of DCs into tumors.
a, cDC gating strategy in tumors. b, c, Thy1.1+ Pmel-1 Tc1 or Tc9 cells were transferred into Thy1.2+ B6 mice bearing MC38 chimeric tumors with the adjuvant treatment, and tumor tissues were harvested for analysis. Percentages and numbers of cDCs in tumors tissues (b, n = 6 mice per group, one of two independent experiments), number of cDC2 in tumors tissues (c, n = 6 mice per group, one of two independent experiments). d, cDC gating strategy in tdLN. e, f, Thy1.1+ Pmel-1 Tc1 or Tc9 cells were transferred into Thy1.2+ B6 mice bearing MC38 chimeric tumors with the adjuvant treatment, and tdLN were harvested for analysis. Percentages of total migratory cDCs (e, n = 8 mice per group, pooled from two independent experiments) and CD11b+ migratory cDC2 in CD45+ cells in tdLNs (f, n = 8 mice per group, pooled from two independent experiments). g, CD4+ T cell gating strategy in Fig. 5g. h, Schema of experiments in Fig. 6a-f. i, j, Thy1.1+ Pmel-1 Tc9 cells were transferred into Thy1.2+ B6 mice bearing chimeric tumor with the adjuvant treatment, and CCR7 expression on cDC2 cells from tumor tissues (i, n = 4 mice per group, one of two independent experiments) or tdLNs (j, n = 4 mice per group). k, Schema of experiments in Fig. 6g-m. Data are presented as mean ± SEM. Two-tailed unpaired Student’s t-tests were used in b, c, e, f, i, j.
